Clinical trials: Amyloidosis
Alzheimer´s Disease
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to…
- Trial name
- NCT00818662
- Testing
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Where
- 41 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Baxalta now part of Shire
Transthyretin Cardiac Amyloidosis
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
Transthyretin cardiac amyloidosis (ATTR-CA) is a relentlessly progressive disease that can progress to end stage heart failure, at which point recently approved transthyretin production silencing or structure stabilizing…
- Trial name
- NCT05489523
- Testing
- Tafamidis 61 MG
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
Dementia is a common neurodegenerative syndrome in aged population. Alzheimer's disease (AD) is the most common disease. The main pathological findings in AD include senile plaques (SP) and neurofibrillary tangles (NFT).
- Trial name
- PMPBB3/AV45 (NCT04305210)
- Testing
- F-18 PMPBB3, 18F-florbetapir
- Where
- Taiwan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer Disease
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- AV94 (NCT00605059)
- Testing
- [123I]AV94
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Amyloidosis
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. II.
- Trial name
- NCT00017680
- Testing
- Melphalan, Autologous Stem Cell Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Amyloid Light-chain Amyloidosis
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition.
- Trial name
- NCT07524634
- Testing
- BCMA bispecific
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT01960348
- Testing
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Where
- 52 sites in United States, Argentina and 19 more
- Volunteers
- 225 people
- Sponsor
- Alnylam Pharmaceuticals
Down Syndrome (DS)
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in…
- Trial name
- NCT01699711
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Spain
- Volunteers
- 87 people
- Sponsor
- Parc de Salut Mar
Alzheimer's Disease (AD)
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation.
- Trial name
- AmyClearAD (NCT05059158)
- Testing
- positron emission tomography (PET)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Sleep, Alzheimer Disease
Sleep Trial to Prevent Alzheimer's Disease
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
- Trial name
- SToP-AD (NCT04629547)
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Cardiovascular Disease Other
CARDIOVASCular Unexpected fiNdings in patiEnts Undergoing eXecution of PET/tc
The goal of this single-center observational study is to retrospectively evaluate incidental findings at the cardiovascular level in a selection of patients referred to the O.U.
- Trial name
- CV-UNEXPET/TC (NCT06774391)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Amyloidosis
Mixed Chimeric Transplantation for Primary Amyloidosis
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
- Trial name
- NCT00186095
- Testing
- autologous followed by nonmyeloablative allogeneic transplant
- Sponsor
- Stanford University
Amyloid Transthyretin Cardiomyopathy
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with…
- Trial name
- NCT04360434
- Testing
- NI006
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 46 people
- Sponsor
- Neurimmune AG
Multiple Myeloma, Lymphoma
Ixazomib Rollover Study
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
- Conditions
- Multiple Myeloma, Lymphoma, Amyloidosis
- Trial name
- NCT02924272
- Testing
- Ixazomib
- Where
- 26 sites in United States, Belgium and 9 more
- Volunteers
- 32 people
- Sponsor
- Takeda
Arrythmia, Cardiac Amyloidosis
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
The overall aim of this study is to improve our understanding of the effects of the build-up of amyloid deposits in the heart, in particular, our understanding of the risk of abnormal heart beats, or rhythms, associated with…
- Conditions
- Arrythmia, Cardiac Amyloidosis, Sudden Cardiac Death
- Trial name
- EXCALIBUR (NCT04856267)
- Testing
- LINQ device - implantable cardiac monitor - referred to in the application as "implantable loop recorder" or "ILR")
- Where
- United Kingdom
- Volunteers
- 110 people
- Sponsor
- Marianna Fontana
Alzheimer's Disease
The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease
The miRNA 107 gene is increasingly appreciated to serve key functions in humans. The miRNA regulate gene expression involved in cell division, metabolism, stress response, and angiogenesis in vertebrate species.
- Trial name
- NCT01819545
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Effect of LY2062430 on the Progression of Alzheimer's Disease
Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to…
- Trial name
- EXPEDITION (NCT00905372)
- Testing
- LY2062430
- Where
- 85 sites in United States, Argentina and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Transthyretin Cardiac Amyloidosis
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging.
- Trial name
- ATTR-AI (NCT05772091)
- Where
- 4 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Pr. Nicolas GIRERD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.